Abbott: Progress Seen, But Buyer Beware
Abbott Laboratories: A Better Picture, But Still Not My Buy List Hey everyone, Sarah Miller here. You know, I’ve been digging into the financial health of Abbott Laboratories (ABT) lately, and it’s a story that’s definitely more interesting than it was five years ago. For those of you who follow my market analysis, you know I’m always looking at the long game, especially when it comes to healthcare stocks. They’re often seen as defensive plays, which is tempting in today’s uncertain economic climate. ...